Your browser doesn't support javascript.
Factors associated with development and persistence of post-COVID conditions: A cross-sectional study.
Miyazato, Yusuke; Tsuzuki, Shinya; Morioka, Shinichiro; Terada, Mari; Kutsuna, Satoshi; Saito, Sho; Shimanishi, Yumiko; Takahashi, Kozue; Sanada, Mio; Akashi, Masako; Kuge, Chika; Osanai, Yasuyo; Tanaka, Keiko; Suzuki, Michiyo; Hayakawa, Kayoko; Ohmagari, Norio.
  • Miyazato Y; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan. Electronic address: ymiyazato@hosp.ncgm.go.jp.
  • Tsuzuki S; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku Univers
  • Terada M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
  • Kutsuna S; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Saito S; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
  • Shimanishi Y; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Takahashi K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Sanada M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Akashi M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Kuge C; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Osanai Y; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Tanaka K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Suzuki M; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Hayakawa K; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
J Infect Chemother ; 28(9): 1242-1248, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1851526
ABSTRACT

INTRODUCTION:

The post-COVID condition has become a social concern. Although the patient characteristics associated with the development of this condition are partially known, those associated with its persistence have not been identified.

METHODS:

We conducted a cross-sectional questionnaire-based survey among patients who had recovered from COVID-19 and visited the National Center for Global Health and Medicine between February 2021 and March 2021. Demographic and clinical data, and data regarding the presence and duration of post-COVID conditions were obtained. We identified factors associated with the development and persistence of post-COVID conditions using multivariate logistic and linear regression analyses, respectively.

RESULTS:

We analyzed 457 of 526 responses (response rate, 86.9%). The median patient age was 47 years. Of these, 378 patients (84.4%) had mild disease in the acute phase. The number of patients with symptoms at 6 and 12 months after onset or diagnosis was 120 (26.3%) and 40 (8.8%), respectively. Women were at risk of developing fatigue (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.31-3.14), dysosmia (OR 1.91, 95%CI 1.24-2.93), dysgeusia (OR 1.56, 95%CI 1.02-2.39), hair loss (OR 3.00, 95%CI 1.77-5.09), and persistence of any symptoms (coefficient 38.0, 95%CI 13.3-62.8). Younger age and low body mass index were factors for developing dysosmia (OR 0.96, 95%CI 0.94-0.98 and OR 0.94, 95%CI 0.89-0.99, respectively) and dysgeusia (OR 0.98, 95%CI 0.96-1.00 and OR 0.93, 95%CI 0.88-0.98, respectively).

CONCLUSION:

We identified factors involved in the development and persistence of post-COVID conditions. Many patients, even those with mild conditions, experience long-term residual symptoms.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Olfaction Disorders Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Olfaction Disorders Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article